Arts E, Anthoni H, de Roy G, D'Hollander J, Verhaegen H
J Int Med Res. 1979;7(2):158-61. doi: 10.1177/030006057900700208.
Domperidone, at a dosage of 20 mg t.d.s before meals, in a double-blind, crossover, placebo-controlled trial reduced the level of the symptoms of dyspepsia by 76% compared to a 16% reduction with placebo. This difference was statistically significant (p less than 0.001). Thirteen of the fourteen patients in the study preferred domperidone to placebo. Four patients in the active treatment period and one in the placebo complained of mild side-effects.
在一项双盲、交叉、安慰剂对照试验中，多潘立酮以每日三次、每次20毫克的剂量于饭前服用，与安慰剂组16%的消化不良症状减轻程度相比，其消化不良症状水平降低了76%。这一差异具有统计学意义（p小于0.001）。该研究中的14名患者中有13名更喜欢多潘立酮而非安慰剂。在积极治疗期，有4名患者，在安慰剂组有1名患者抱怨出现了轻微副作用。
